A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects

Inclusion Criteria Concurrent Medication: Required: * Omeprazole given concurrently in patients receiving the oral vaccine dose. Volunteers must have: * HIV-1 negativity. * Normal history and physical exam. * Lower risk for HIV infection. * CD4 count \>= 400 cells/mm3. * Normal urine dipstick with esterase and nitrite. NOTE: * No more than 10 percent of volunteers may be over age 50. Exclusion Criteria Co-existing Condition: Volunteers with the following conditions are excluded: * Positive for hepatitis B surface antigen. * Medical or psychiatric condition (including recent suicidal ideation or present psychosis) that precludes compliance. * Occupational responsibilities that preclude compliance. * Active syphilis (NOTE: If serology is documented to be a false positive or due to a remote (\> 6 months) infection, subject is eligible). * Active tuberculosis (NOTE: Subjects with a positive PPD and normal x-ray showing no evidence of TB and who do not require INH therapy are eligible). Volunteers with the following prior conditions are excluded: * History of immunodeficiency, chronic illness, malignancy, autoimmune disease, or use of immunosuppressive medications. * History of cancer unless surgically excised with reasonable assurance of cure. * History of suicide attempts or past psychosis. * History of anaphylaxis or other serious adverse reactions to vaccines. * History of serious allergic reaction requiring hospitalization or emergent medical care. Prior Medication: Excluded: * Prior HIV-1 vaccines or placebo in an HIV vaccine trial. * Live attenuated vaccines within the past 60 days. NOTE: Medically indicated subunit or killed vaccines (e.g., influenza, pneumococcal) do not exclude but should be administered at least 2 weeks prior to HIV immunizations. * Experimental agents within the past 30 days. Prior Treatment: Excluded: * Blood products or immunoglobulin within the past 6 months. Higher risk behavior for HIV infection as determined by screening questionnaire, including: * History of injection drug use within the past year. * Higher or intermediate risk sexual behavior.